NCT06586047RecruitingEarly phase 1
Breast Cancer PSMA PET
Evaluation of PSMA Expression in Triple Negative Breast Cancer Patients Using 18 F-DCFPyL-PET/CT
Source: ClinicalTrials.gov · Last updated 6 Aug 2026
Brief summary (registry, in English)
The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 3 Sept 2024
- Start date
- 29 Aug 2024
- Primary completion date
- 29 Dec 2026
- Lead sponsor
- Ahmad Shariftabrizi
- Diseases
- Triple-negative breast cancer
- NCT number
- NCT06586047
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 30
- From 29 Aug 2024 to the primary completion date, 29 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with known active other malignancy.
- Patients with any medical condition that might compromise the safety of subject during PET acquisitions.
Other
- Unable to tolerate PET/CT procedure.
- Pregnant or breastfeeding.
Who the study is looking for
- Female \>= 18 years of age
- Patients in distantly metastatic TNBC based on the initial diagnosis biopsy.
- Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included.
Age in the registry: 18 years to 90 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Iowa Healthcare Coordinator of this site? Confirm its status | Iowa City | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.